Brief: Calidi Biotherapeutics Entered Into A Standby Equity Purchase Agreement
Dec 12 (Reuters) - Calidi Biotherapeutics Inc CLDI.A :
* CALIDI BIOTHERAPEUTICS INC - ON DEC 10, ENTERED INTO A
STANDBY
EQUITY PURCHASE AGREEMENT
* CALIDI BIOTHERAPEUTICS INC - WILL HAVE RIGHT, BUT NOT
OBLIGATION, TO SELL TO YORKVILLE UP TO $25 MILLION OF ITS SHARES
OF COMMON STOCK
Further company coverage: CLDI.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma